Novel Therapeutics and Drug Targets 1

• 431 · PDF 一种用于特异性检测的新方法学（NAM）：膜蛋白质组阵列的ISTAND资格认证以评估基于单克隆抗体疗法的脱靶结合 A new approach methodology (NAM) for specificity testing: ISTAND qualification of the membrane proteome array to evaluate off-target binding of MAb-based therapies Diana Norden, Jonathan T. Sullivan, Carmen Navia, Jonathan Richards, Alexander Hobby, Rachel Fong, Benjamin Doranz
• 432 · PDF 用小分子靶向Brachyury：脊索瘤和神经内分泌癌的新治疗范式 Targeting Brachyury with small molecules: A new therapeutic paradigm for chordoma and neuroendocrine carcinomas Gaelle Mercenne, Brian McEllin, Julia Robbins, Lindsay Pino, Gavin Hirst, Alexander Joel Federation
• 433 · PDF 一种用于精确定量致癌蛋白的稳健自动化工作流程，以加速靶向降解和肿瘤学研究 A robust automated workflow for precise oncoprotein quantification to accelerate targeted degradation and oncology research Alex M. Strom, Quynh Nguyen, Qiuyan Ma
• 434 · PDF 靶点不可知的噬菌体展示技术用于筛选改变免疫细胞功能的纳米抗体 Target agnostic phage display for nanobodies that alter immune cell function Peter Qian Leung, Todd A. Aguilera, Eslam A. Elghonaimy, Thillai Sekar, Mike Whitney, Isaac Gonzalez
• 435 · PDF 用于T细胞衔接治疗药物的新型抗CD3重链抗体 Novel anti-CD3 heavy chain-only antibodies for use in T-cell engaging therapeutics Noel Pauli, Hannah Watkins, Paul Khalife, Elizabeth Parker, Cameron Henkel, Todd Boland, Hailey Heston, Christin Strong, Jinfu Zhao, Irina Burnina, Michael Brown, Jessica Dawson, Garrett Rappazzo, Beth Sharkey, Morgan Morrill, Michael Battles, Robert Pejchal, Eric Krauland
• 436 · PDF IP-DNQ 与 rucaparib 联合靶向氧化还原-DNA修复，在 NQO1 阳性肿瘤中诱导氧化性 DNA 损伤及 GSDME 介导的细胞焦亡 Redox-DNA repair co-targeting with IP-DNQ and rucaparib induces oxidative DNA damage and GSDME-mediated pyroptosis in NQO1-positive tumors Soumya Tumbath, Hao Zhou, Jiangwei Wang, Lingxiang Jiang, Elin H. Chen, Celine Thormann, Xiumei Huang
• 437 · PDF 用甲氟喹（mefloquine）靶向 RNA 去甲基化酶 ALKBH5 可增强抗肿瘤免疫并抑制骨肉瘤进展与转移 Targeting RNA demethylase ALKBH5 with mefloquine enhances antitumor immunity and reduces osteosarcoma progression and metastasis Victoria Chen Mai, Daisy Medina, Manjeet K. Rao
• 438 · PDF 多体药物偶联物（MDC）BD200 通过一种新型双靶向模式介导抗肿瘤活性 The multibody drug conjugate (MDC) BD200 mediates anti-tumor activity through a novel dual-targeting mode Michael D. Oberst, Dror Luger, Micheal Kebede, Devi Gunasekera, Meital Gadrich, Yonit Ben David, Leah Asulin, Noam Grossman, Reut Fuchs, Hezi Sasson, Yael Diesendruck, Guy Nimrod, Tim Wyant, Ronald Herbst, Yanay Ofran, Inbar Amit
• 439 · PDF 在 4NQO 诱导的口腔鳞状细胞癌中，二氯乙酸（dichloroacetate）与氯喹（chloroquine）在亚砷酸盐存在下抑制细胞外基质重塑及转移活性 Inhibition of extracellular matrix remodeling and metastatic activity by dichloroacetate and chloroquine in the presence of arsenite in 4nqo-induced oral squamous cell carcinoma Mounia Benbelkacem, Nabila Moulai, Eimen Kais Kadri, Lina Stamboul, Henni Chader, Wahiba Ouhaioune, Mehdi Bourouba
• 440 · PDF 靶向致癌性 TBRI 信号可抑制雄激素非依赖性前列腺癌的生长与转移 Targeting oncogenic TBRI signaling inhibits androgen-independent prostate cancer growth and metastasis Per Flodbring Larsson, Alexej Schmidt, Yabing Mu, Guangxiang Zang, Jie Song, Vishnupriya Gajavilli, Junting Tao, Olena Rahkimova, Madelene Ericsson, Karthik Aripaka, Sofia Halin Bergstroem, Wei Yuan, Denisa Bogdan, Aaron Zhang, Jon Welti, Anders Bergh, Johann de Bono, Carl-Henrik Heldin, Marene Landstroem
• 441 · PDF 打破 KRAS 抑制剂诱导的耐药壁垒：靶向 KRAS-SOS1 以瓦解缺氧生存 Breaking the KRAS inhibitor induced resistance-wall: Targeting KRAS-SOS1 to disarm hypoxic survival Jooyun Byun, Heesun Moon, Jongmin Hong, Soye Jeon, Jaeyul Choi, Seung Hyun Jung, Yongjae Park, YoungGil Ahn, In Young Choi
• 442 · PDF 削弱癌症的能量与逃逸：NAMPT 与 BCL2 作为 T-ALL 中的双靶点 Crippling cancer's energy and escape: NAMPT and BCL2 as dual targets in T-ALL John Robert Sanchez, Daisy Diaz-Rohena, Valerio Ciaurro, Min Wu, Francis Roushar, Dennise A. De Jesus-Diaz, Gregory Crimmins, Pratibha Sharma, Vinay Puduvalli, Francisco Vega, Palaniraja Thandapani, Deepa Sampath
• 443 · PDF LMTK2：ERalpha+ 乳腺癌中内分泌耐药的一种新型驱动因子 LMTK2: A novel driver of endocrine resistance in ERalpha+ breast cancer Anna Detry, Sofia Marigliano, Jenna Heinen, Adam Bass, Calley Jones, Rajeev Muthyala, Matthew Goetz, John Hawse
• 445 · PDF 评估HERV-K作为一种非常规癌症治疗靶点 Evaluation of HERV-K as an unusual cancer therapeutic target Monica Gordon, James H. Torpey, Andy D. Martin, Benjamin R. Miller, Marica Speranza, Kenneth W. Hance
• 446 · PDF 点击化学预靶向促进CEACAM5阳性肿瘤中MMAE的选择性激活：一种增强靶向治疗临床获益的同类首创方法 Pre-targeting with click chemistry facilitates selective MMAE activation in CEACAM5+ tumors: A first-in-class approach to enhance clinical benefit in targeted therapy Sangeetha Srinivasan, Maša Alečković, George Coricor, Stefanie Wagner, Jesse M. McFarland, Nathan A. Yee, Tri-Hung Nguyen, Michael Zakharian, Travis L. Biechele, Jose M. Mejia Oneto
• 447 · PDF 一种靶向M2样肿瘤相关巨噬细胞的纳米颗粒TLR7/8激动剂UI-102重编程其表型以诱导强效抗肿瘤免疫 A M2-like tumor-associated macrophage-targeted nanoparticulate TLR7/8 agonist, UI-102, reprograms its phenotypes to induce potent anti-tumor immunity Yasuhiro Nagai, Ayaka Matsumoto, Nami Mizoguchi, Mina Tsukamoto, Junki Tashiro, Tadashi Inoue, Takatoshi Soga, Naozumi Harada
• 448 · PDF 针对头颈部鳞状细胞癌前哨淋巴结的结内趋化因子治疗 Intranodal chemokine therapy targeting the sentinel lymph node in head and neck squamous cell carcinoma Anais Aurelia Zourelidis, Jonathan Gunn, Tomoya Kurokawa, Sayuri Miyauchi, Kelsey Decker, Peter Vo, Pardis Mohammadzadeh, Jason Wu, Ester J. Kwon, Joseph A. Califano
• 449 · PDF 基于白蛋白的DLL3靶向SN38纳米免疫偶联物在小细胞肺癌中保持效力并显示出高亲和力DLL3结合 Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer Mohamed Shanshal, Lin Yang, Liyi Geng, Wendy Nevala, Aaron S. Mansfield, Bharath Wootla, Konstantinos Leventakos, Kyle Korshavn, Svetomir N. Markovic
• 450 · PDF JZY-2233：一种用于晚期前列腺癌治疗的抗原靶向CBP/p300降解剂-抗体偶联物 JZY-2233: An antigen-targeted CBP/p300 degrader-antibody conjugate for advanced prostate cancer therapy Mi Wang, Jianzhang Yang, Brandon Bordeau, Shicheng Jin, Yu Wang, Shaomeng Wang
• 451 · PDF 研究SIX1作为头颈部鳞状细胞癌中同类首创EMT降解剂的驱动因子和靶点 Investigating SIX1 as a driver and target for a first in-class EMT degrader in head-and-neck squamous cell carcinoma Vic Scharfenberger, Asad Faili, Lucia Zoe Miehe, Ellen Weber, Samaneh Heydarzadeh, Reinhard Buettner, Tristan Lerbs
• 452 · PDF AURKA抑制在ER+炎性乳腺癌中的治疗潜力 Therapeutic potential of AURKA inhibition in ER+ inflammatory breast cancer Tanu Sharma, Azadeh Nasrazadani, Ma Wencai, Jennifer Chen, Megumi Kai, Bora Lim, Michael Lewis, Lacey Dobrolecki, The MDACC IBC Team, Nikita Kotlov, Oleg Baranov, Disha Malani, Daria Goncharova, Anastasiya Evdokimova, Francesca Paradiso, Michael Hensley, Rachel Layman, Wendy Woodward
• 453 · PDF 以SERPINB3为靶点的小分子作为宫颈癌的抗癌策略 Small molecule targeting of SERPINB3 as an anticancer strategy in cervical cancer Sarah Yu, Liyun Chen, Eric Liu, Ethan Memming, Clifford Luke, Gary Silverman, Stephanie Markovina
• 454 · PDF 以首创的双模式药物克服PD-1抵抗，将"冷"肿瘤转化为"热"肿瘤 Overcoming PD-1 resistance with a first-in-class dual-mode agent that transforms ‘cold' tumors to ‘hot' Tong Zhu, Lixin Li
• 455 · PDF MC001：一种用于治疗表达叶酸受体α的胰腺癌的新型化学免疫治疗抗体药物偶联物 MC001: A novel chemoimmunotherapy antibody drug conjugate for treating folate receptor alpha expressing pancreatic cancer Seah H. Lim, Hailiang Zheng, Peipei Zhong, Tawei Huang
• 456 · PDF 借助结构蛋白质组学和AI发现KAT6A降解剂 Discovery of KAT6A degrader enabled by structural proteomics and AI Yonatan Kedem, Nitzan Simchi, Anjana Shenoy, Andrew Morley, Alon Shtrikman, Michal Ran Shchory, Yaron Ben Shoshan-Galeczki, Dimitri Kovalerchik, Iris Alchanati, Galina Otonin, Noam Cohen, Gali Arad, Eran Seger, Kirill Pevzner
• 457 · PDF 奈必洛尔在三阴性乳腺癌中触发凋亡、铁死亡和坏死性凋亡 Nebivolol triggers apoptosis, ferroptosis and necroptosis in triple-negative breast cancer Wangjia Cao, Anh Vuong, Somik Chattertjee, Tagari Samanta, Radbod Darabi, Ashok Kumar, Benny A. Kaipparettu, Meghana Trivedi
• 1320 · PDF 针对pan-mKRAS或PTEN缺失肿瘤的靶向肽药物偶联物（Maleimide-KGDEVD-Doxorubicin/Exatecan）的1期临床试验中期结果 Interim results of clinical trial phase 1 of pan-mKARS or PTEN loss tumor targeting peptide drug conjugates (Maleimide-KGDEVD-Doxorubicin/Exatecan) Byoungmo Kim, Ha Kyeoung Lee, Yun-Gun Ko, Kyu-pyo Kim, Youngro Byun, Sang Yoon Kim
• 5646 · PDF 用于抗体药物偶联物开发的全人源单克隆抗体，靶向在未满足需求的癌症中表达的一种细胞表面靶点 Fully human monoclonal antibodies for antibody drug conjugate development to a cell surface target expressed in cancers with unmet needs Ginette Serrero, Jorge Marquez, Jianping Dong, Jun Hayashi
• 7455 · PDF CCL5和内皮糖蛋白在ER阳性乳腺癌中的治疗潜力 The therapeutic potential of CCL5 and endoglin in ER-positive breast cancer Dominick Lomonaco, Kideok Jin

在会议检索中浏览本分会场